Annual Report 2024

Culture.
Passion.
Impact.


KEY FIGURES 20241

2.5BN

Revenue in CHF

6.7M

Smiles impacted3

<12 000

Employees

13.7%

Organic revenue growth

82

Employee engagement score

39%

Women in leadership positions4

26%

Core EBIT margin

77

Learning and growth score

40%

Educational activities in low- and middle-income countries

0.95

Dividend2 per share in CHF

100%

Renewable energy

-19%

GHG emissions compared to 2021 (Scope 1+2) t CO2e

1 Figures refer to continuing operations, following the agreement signed in August 2024 to sell the Group’s DrSmile business to Impress Group, which was subsequently completed in September 2024.
2 Subject to AGM approval
3 1 ortho case sold = 1 smile and 2 implants sold = 1 smile
4 According to new calculation methodology


Letter from the Chair and CEO

Chair and CEO

Petra Rumpf, Chair and Guillaume Daniellot, Chief Executive Officer

Dear Reader,

In 2024, we once again performed and transformed, continuing our journey to become the most customercentric and innovative oral care company. We achieved exceptional results, driven by the dedication and passion of our teams, the loyalty of our customers, and the trust of our shareholders.

“6.7 million smiles helped in 2024, 1.1 million more than last year.”

What is our superpower?

“We don’t have the fear of failure (…). We can dare to try. We can be bold because we really have this passion for learning, the agility, the entrepreneurial mindset, the psychological safety… And in my opinion, this makes us unstoppable.”

Daniela Felipucci, Head of Strategic Projects Medical Education


Performance by region1

North America (NAM)

North America
697 M

Revenue in CHF
+3.6% organic revenue

28%

of Group revenue
+1.2% change in CHF


Europe, Middle East, Africa (EMEA)

Europe, Middle East, Africa
1 001 M

Revenue in CHF
+11.3% organic revenue

40%

of Group revenue
+9.0% change in CHF


Latin America (LATAM)

Latin America
217 M

Revenue in CHF
+15.6% organic revenue

9%

of Group revenue
+4.3% change in CHF

Asia Pacific (APAC)

Asia Pacific
588 M

Revenue in CHF
+33.3% organic revenue

23%

of Group revenue
+27.7% change in CHF

1 Figures refer to continuing operations, following the agreement signed in August 2024 to sell the Group’s DrSmile business to Impress Group; the sale was completed in September 2024.


How did my new smile help me unlock my true potential?

“For me, a radiant smile  was more than just an aspiration.”

Karine Perron, patient

Share price development

(Price in CHF)

Share price development

(Price in CHF)


Business Development


In the financial year 2024, we achieved revenue of CHF 2.5 billion and organic revenue growth of 13.7%, or 10.0% growth in Swiss francs after currency headwinds.

Innovation and execution defined 2024 as a standout year for the Group. Advancements in implantology, orthodontics and digital solutions reinforced our position as a leader in dental care in a growing market. The overall addressable market across all business areas grew from CHF 19 billion in 2023 to about CHF 20 billion in 2024.

Our implantology business achieved double-digit revenue growth in both the premium and challenger segments, contributing to the strong 2024 performance. Consequently the Group estimates that its market share in implantology has grown from approximately 32% to 35%. The ClearCorrect and digital solutions businesses also grew double-digit globally, contributing to the strong performance and solidifying the Group’s market position.

Alongside its focus on innovation, execution and organic growth, the Group continued to make significant investments in production capacity, digital transformation and the development of its workforce. Strong top line growth combined with those continued investments translated into an EBIT margin of 27.6% at constant 2023 currency exchange rates .

Despite persistent macroeconomic uncertainties, we continued to make a meaningful global impact, helping 5.6 million smiles in 2023 and growing to 6.7 million smiles in 2024.

Key performance figures1

  2024
Core2
2023
Core2
Revenue (CHF m) 2 503.9 2276.7
Gross profit margin (%) 71.4 74.5
EBIT margin (%) 26.0 28.0
Net profit margin (%) 20.0 21.2

1 Figures refer to continuing operations following the agreement signed in August 2024 to sell the Group’s DrSmile business to Impress Group; the sale was completed in September 2024.
2 To facilitate a like-for-like comparison, the Group presents ‘core’ results in addition to the results reported under IFRS Accounting Standards.

The Business development includes the following chapters
Business performance
Share performance

HOW DO YOU ENVISION DENTISTRY IN 10 YEARS?

“I decided I want to enjoy what I’m doing and stay true to my purpose and enthusiasm.”

Dr. Óscar González-Martín

Sustainability report


100%

Renewable electricity at our own manufacturing

39%

Of leadership positions held by women1

77

Learning and growth score

8 781 T CO₂E

Greenhouse gas emissions
Scope 1

40%

Educational activities in low- and middle-income countries

94%

Sales compliance e-training mean completion rate

6.7 M

Smiles helped

1 432 T CO₂E

Greenhouse gas emissions
Scope 22

1 Based on new calculation methodology
2  Market-based emissions


WHAT ARE THE PAIN POINTS FOR DENTAL LABS?

“You are my thirdparty manufacturing partner I can rely on anytime.”

Jack Marrano,
Director of Signature Prosthetics at Absolute Dental Services,
located in Durham, North Carolina, US

Corporate governance report

The principles, structures, mechanisms and controls by which the Straumann Group is directed and the people who are responsible for their execution.


Compensation report

This report provides a comprehensive overview of the Straumann Group’s compensation principles, practices and delivery framework. It also provides information on the compensation of the general staff, management, Executive Management Board (EMB) and Board of Directors (BoD).


Financial report

The consolidated financial statements of the Straumann Group for the year ended 31 December 2024 were authorized for issue in accordance with a resolution of the Board of Directors on 17 February 2025 and are subject to approval by the annual general meeting on 10 April 2025.

Downloads